Cardiogen Australia — Short Peptide Bioregulator Research
From $99 AUD · ≥98% HPLC purity · third-party COA · ships Australia-wide
What is Cardiogen?
Cardiogen (Ala-Glu-Asp-Arg, AEDR) is a synthetic tetrapeptide bioregulator of the Khavinson class studied in cardiac-tissue research. Developed at the St Petersburg Institute of Bioregulation and Gerontology, it is investigated in preclinical studies of myocardial tissue and cardiomyocyte gene expression.
Specifications
- From: $99 AUD
- Category: Longevity & Bioregulators
- Form: Lyophilised powder
- Purity: ≥98% HPLC
- Testing: Third-party Certificate of Analysis
- Classification: Research reference material · For Research Use Only
What the research covers
Cardiogen is a synthetic tetrapeptide from the Khavinson peptide bioregulator series, reported as Ala-Glu-Asp-Arg, abbreviated AEDR. It is the member of that family assigned to cardiac tissue and was developed within the same programme at the St Petersburg Institute of Bioregulation and Gerontology that produced the other short tissue-assigned peptides stocked in this catalogue.
As with its siblings, the evidence position comes first. The reported sequence is consistently attributed across secondary and commercial sources but we could not trace it to an accessible peer-reviewed primary publication in English. The searchable record for this compound is dominated by vendor material, and what primary research exists appears to sit in Russian-language journals or in publications from the originating institute. Independent replication by unaffiliated laboratories could not be identified, and no clinical evidence of any weight exists. A page that presented this compound as having an established research base would be misrepresenting the record.
The framework it belongs to is the bioregulator premise: that very short peptides of two to four residues enter cells and interact with specific DNA regions to modulate transcription selectively by tissue, with Cardiogen's described tissue being myocardium. That premise is characteristic of this tradition and is not broadly accepted outside it, since sequence-specific DNA recognition is understood in mainstream molecular biology to require structural complexity that a four-residue peptide does not possess.
What distinguishes Cardiogen chemically from Bronchogen, the sibling it most resembles, is the C-terminal residue: arginine rather than leucine by the reported sequences. That single substitution changes the molecule from one with a net negative character to one with a strongly basic guanidinium group, which alters solubility, isoelectric behaviour and chromatographic retention appreciably. It is a real chemical difference despite the sequences being three-quarters identical.
TXLABS supplies Cardiogen as an analytical reference material for laboratory research only. It is not an approved therapeutic good in Australia and is not supplied for human or veterinary administration.
Reading the certificate
Two questions dominate a certificate for this compound. The first is identity, and because there is no accessible published specification to check against, the certificate defines the material rather than confirming it: ask for the observed mass as a number and for the sequence as the manufacturer states it. The second is the pair of chemistry-specific species. The isoaspartate isomer from the aspartate residue is isobaric with the parent and can only be resolved chromatographically, so ask whether the method separates it. Salt form and net peptide content matter disproportionately for a basic peptide of this size, where counterion content can be a large fraction of gross vial weight; an arginine-containing peptide is typically supplied as an acetate or trifluoroacetate salt and the two differ appreciably in that share. TXLABS publishes third-party certificates for tested lots in the CoA library; no certificate is currently published for Cardiogen. The lot certificate is available on request to support@txlabs.bio.
Storage and handling
The reported sequence carries two features worth attention. The aspartate residue provides the aspartimide route: cyclisation in aqueous solution followed by resolution to a mixture of aspartate and isoaspartate forms, driven by warmth and by pH away from neutral, producing a species isobaric with the parent. The C-terminal arginine, meanwhile, gives the peptide a strongly basic character despite two acidic residues, which makes it very water-soluble and also makes it adsorb to negatively charged surfaces; at dilute working concentration that adsorption is measurable. The guanidinium group is chemically stable but hygroscopic, so the lyophilised solid takes up atmospheric moisture readily. There is no cysteine, methionine or tryptophan, so oxidation is not a concern.
Store the lyophilised powder at -20 C, desiccated and protected from light, and equilibrate the sealed vial before opening; with a hygroscopic basic peptide this is more than a formality. Hold solutions at 2-8 C near neutral pH and aliquot rather than freeze-thaw. As a dry solid it tolerates Australian summer freight reasonably well, but heat with absorbed moisture drives aspartimide chemistry, so dry, cold storage is the right default.
Working out concentration
The TXLABS Cardiogen vial is 20 mg. Twenty milligrams into 2 mL of bacteriostatic water gives 10 mg/mL; into 4 mL, 5 mg/mL; into 10 mL, 2 mg/mL. High concentrations are readily achievable because the C-terminal arginine makes the peptide strongly basic and very soluble. A molar figure is not given here, because the molecular weight of the commercial material could not be confirmed from an authoritative source; the mass reported on the certificate for the lot supplied should be used for any molarity calculation. Note that the sibling compound Bronchogen at the same vial size and volume gives the same mass concentration but a different molar one, since the two differ in a terminal residue. The reconstitution calculator handles the arithmetic. Concentration examples only, not a protocol.
How it relates to adjacent compounds
Bronchogen is Cardiogen's nearest relative in this catalogue: the same series, the same reported design, and by the conventional attributions the same first three residues, differing only at the C-terminus. That near-identity is itself instructive, because it means the two cannot be distinguished by any test that does not resolve their small mass difference. Pinealon is the tripeptide member of the family. Epithalon is the best documented member and the most useful starting point for anyone assessing how much weight the tradition's literature bears. Thymalin represents its earlier tissue-extract generation. These are tradition and structural adjacencies only, and imply nothing about comparable activity or interchangeable use.